==============================
TICKER: JANX
==============================

Role: Momentum hedge fund analyst. You are running a probability audit (NOT a price predictor).
Objective: Decide if JANX has >60% probability of achieving +10% within 30 calendar days.

Hard constraints:
- You MUST penalize "Unknown" earnings + missing headlines (no assuming hidden catalysts).
- You MUST still score based on tape structure: RVOL, ATR%, RSI, distance to 52W high, setup type.
- You MUST output at most 2 BUY ratings across the entire batch (if you are given multiple tickers).
- If catalyst data is weak, default to WATCH/IGNORE even if technicals look good.
- If Dilution risk flag = 1 (headline scan), cap Verdict at WATCH unless there is a clear positive catalyst that outweighs it.
- For Breakouts, require structural confirmation: Above_MA20=1 and Above_MA50=1; otherwise downgrade Technical Alignment.

Inputs:
Market regime snapshot (best-effort):
- SPY=681.88 vs MA20=671.17 (OK); VIX=16.08 (<= 25.00 is OK).
- Regime Gate OK: True

Earnings (best-effort): Unknown

Screener metrics:
- Last: 17.11
- RVOL: 2.63
- ATR%: 19.2 (≈ $3.29 ATR/day)
- RSI14: 31.3
- Dist_to_52W_High%: 64.04

- MA20: 28.52
- MA50: 26.79
- Above_MA20: 0 (1=yes, 0=no)
- Above_MA50: 0 (1=yes, 0=no)
- Ret20d%: -36.65%
- Setup: Reversal
- Score: 43.22
- Leveraged ETF: NO
- Source tags: BASE_UNIVERSE
- Dilution risk flag (headline scan): 0
- Catalyst tags (headline scan): regulatory


Catalyst completeness (penalize Unknowns):
- Completeness Score: 25/100
- Earnings known: False (earnings=Unknown)
- Recent headline count (14d): 0
- Manual headlines: False
- Penalties:
  * Earnings date Unknown (penalize catalyst clarity).
  * No recent headlines found (penalize narrative visibility).


Recent headlines:
- [2025-12-27 12:43 UTC] : Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)
- [2025-12-12 12:30 UTC] : 2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential
- [2025-12-06 11:09 UTC] : Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test?
- [2025-12-05 03:16 UTC] : Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop
- [2025-12-02 21:14 UTC] : Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'?
- [2025-12-02 20:53 UTC] : Sector Update: Health Care Stocks Softer Late Afternoon
- [2025-12-02 19:25 UTC] : Top Midday Decliners
- [2025-12-02 15:50 UTC] : Janux dives as gaps in prostate cancer study data worry investors
- [2025-12-02 14:53 UTC] : Janux Therapeutics Stock Craters After ‘Positive’ Cancer  Data. Why It’s Down 50%.
- [2025-12-02 14:13 UTC] : Traders Tread Cautiously as Key Inflation Metric Looms, Driving Narrow Premarket Gains for US Equity Futures

Standard trade plan template (by setup):
- Entry: Reclaim MA20 (or prior swing level) AND RSI curl up; confirm with a green day + elevated volume.
- Stop: Below recent swing low OR 1.0–1.3× ATR below entry (whichever is tighter and logical).
- TPs: TP1 = MA50 / prior supply zone, TP2 = gap-fill / next resistance; reduce into strength.
- Position sizing: risk 1–2% of account per trade. Shares = (AccountRisk$) / (StopDistance$).


If data is missing, explicitly state Unknown and list checks:
- Confirm next earnings date (company IR site / Nasdaq earnings calendar).
- Pull 14–30d headlines from a second source (SEC, PR, major outlets, terminal).
- Check upcoming: FDA/clinical readouts, contracts, secondary offering/ATM, lockup expiry, guidance updates.
- Check technical context: multi-year resistance, gap levels, supply zones, post-earnings drift behavior.

Scoring rubric (0–100):
- Catalyst Immediacy (0–30)
- Narrative Velocity (0–25)
- Volatility Fit (0–20)
- Technical Alignment (0–25)

Output format (STRICT):
- Total Score: X/100
- Verdict: BUY / WATCH / IGNORE
- Setup: Breakout or Reversal
- 1-line Spark: what specifically could trigger +10%
- 1-line Trap: what invalidates the thesis
- Trade Plan: entry trigger, stop anchor, TP1/TP2, position size rule (risk 1–2%)


==============================
TICKER: AEO
==============================

Role: Momentum hedge fund analyst. You are running a probability audit (NOT a price predictor).
Objective: Decide if AEO has >60% probability of achieving +10% within 30 calendar days.

Hard constraints:
- You MUST penalize "Unknown" earnings + missing headlines (no assuming hidden catalysts).
- You MUST still score based on tape structure: RVOL, ATR%, RSI, distance to 52W high, setup type.
- You MUST output at most 2 BUY ratings across the entire batch (if you are given multiple tickers).
- If catalyst data is weak, default to WATCH/IGNORE even if technicals look good.
- If Dilution risk flag = 1 (headline scan), cap Verdict at WATCH unless there is a clear positive catalyst that outweighs it.
- For Breakouts, require structural confirmation: Above_MA20=1 and Above_MA50=1; otherwise downgrade Technical Alignment.

Inputs:
Market regime snapshot (best-effort):
- SPY=681.88 vs MA20=671.17 (OK); VIX=16.08 (<= 25.00 is OK).
- Regime Gate OK: True

Earnings (best-effort): Unknown

Screener metrics:
- Last: 23.97
- RVOL: 4.04
- ATR%: 4.16 (≈ $1.00 ATR/day)
- RSI14: 89.1
- Dist_to_52W_High%: 1.8

- MA20: 18.65
- MA50: 17.22
- Above_MA20: 1 (1=yes, 0=no)
- Above_MA50: 1 (1=yes, 0=no)
- Ret20d%: 48.15%
- Setup: Breakout
- Score: 24.5
- Leveraged ETF: NO
- Source tags: BASE_UNIVERSE
- Dilution risk flag (headline scan): 0
- Catalyst tags (headline scan): earnings


Catalyst completeness (penalize Unknowns):
- Completeness Score: 55/100
- Earnings known: False (earnings=Unknown)
- Recent headline count (14d): 10
- Manual headlines: False
- Penalties:
  * Earnings date Unknown (penalize catalyst clarity).


Recent headlines:
- [2026-01-13 16:11 UTC] : American Eagle Lifts Q4 Outlook as Holiday Momentum Powers Sales
- [2026-01-13 16:07 UTC] : URBN Stock Falls 12% Despite Broad-Based Holiday Sales Gains
- [2026-01-13 14:38 UTC] : Tractor Supply Advances Expansion Plans, Introduces Its 2400th Store
- [2026-01-13 14:18 UTC] : Abercrombie Down More Than 17% on Revised View, Issues Business Update
- [2026-01-13 14:00 UTC] : How to Find Strong Retail-Wholesale Stocks Slated for Positive Earnings Surprises
- [2026-01-13 14:00 UTC] : American Eagle Outfitters, Inc. (AEO) Is a Trending Stock: Facts to Know Before Betting on It
- [2026-01-13 12:59 UTC] : Genesco Rallies on Holiday Sales Strength and Higher FY26 View
- [2026-01-13 08:12 UTC] : A Look At American Eagle (AEO) Valuation After Raising Q4 Operating Income Guidance
- [2026-01-13 07:32 UTC] : What to Watch With AEO Stock in 2026
- [2026-01-12 22:00 UTC] : Abercrombie & Fitch, Lululemon: Takeaways from holiday updates

Standard trade plan template (by setup):
- Entry: Break & hold above prior day high OR key resistance on ≥1.5× volume; avoid chasing if >2× ATR extension.
- Stop: 1.2× ATR below breakout level (or below prior day low if tighter and logical).
- TPs: TP1 = +1.0× ATR, TP2 = +2.0× ATR; trail stop after TP1.
- Position sizing: risk 1–2% of account per trade. Shares = (AccountRisk$) / (StopDistance$).


If data is missing, explicitly state Unknown and list checks:
- Confirm next earnings date (company IR site / Nasdaq earnings calendar).
- Check upcoming: FDA/clinical readouts, contracts, secondary offering/ATM, lockup expiry, guidance updates.
- Check technical context: multi-year resistance, gap levels, supply zones, post-earnings drift behavior.

Scoring rubric (0–100):
- Catalyst Immediacy (0–30)
- Narrative Velocity (0–25)
- Volatility Fit (0–20)
- Technical Alignment (0–25)

Output format (STRICT):
- Total Score: X/100
- Verdict: BUY / WATCH / IGNORE
- Setup: Breakout or Reversal
- 1-line Spark: what specifically could trigger +10%
- 1-line Trap: what invalidates the thesis
- Trade Plan: entry trigger, stop anchor, TP1/TP2, position size rule (risk 1–2%)
